Tesamorelin

Molecular Formula – C221H366N72O67S
Molecular Weight – 5136 u
Research Category – Hormone Regulation
Purity – 99.99%
Lab Tested – Yes

Tesamorelin is a GHRH analog designed to reduce visceral fat by stimulating GH secretion with high specificity. It provides a targeted approach to study lipodystrophy, metabolic syndrome, and GH-related fat metabolism. Researching Tesamorelin could improve treatments for obesity and HIV-associated fat disorders.

Tesamorelin (INN) (trade name Egrifta SV) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.